2nd May 2019
Daniel Pfund, Senior Financial Analyst
Alcon was divested from Novartis by distributing one Alcon share for every 5 Novartis shares held. The new company has directly integrated the SMI, replacing Julius Baer. This is not the first time that this ophthalmology specialist has been listed on the stock exchange. Indeed, from 2002 to 2010, a minority of the company (23%) was already listed, the rest belonging to Nestlé at the time. By regaining its freedom, the new management will take its destiny in hand and do everything possible to achieve their objective of an operating margin of around 23% in 2023 (17% in 2018).